Addressing cell and gene therapy challenges through advances in scientific and manufacturing technology

The manufacturing of viral vectors is a major bottleneck in delivering cell and gene therapies to the patient. Reducing the cost of goods while maintaining a high quality of the viral materials requires disruptive changes to the process. A novel approach to vector design through promoter and capsid engineering leads to more effective and specific vectors. Alternatives to the standard transfection-based process improve process efficiency through increased titres and reduced cost of goods. We will discuss challenges and trends within the cell and gene therapy industry, and how advances in technology help accelerate the development of breakthrough therapies.

Attend this webinar for insights into:

• Addressing the complexities of viral vector production for cell and gene therapies
• The benefits of adopting scalable, high-throughput technologies coupled with tailored DoE methodology
• How OXGENE leveraged advanced technologies to expand their know-how and deliver disruptive innovation